NCT05486468 The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
| NCT ID | NCT05486468 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Texas Retina Associates |
| Condition | Uveitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2022-10-05 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 30 participants in total. It began in 2022-10-05 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)
Eligibility Criteria
Inclusion Criteria: General Inclusion Criteria: 1. Male or non-pregnant female in good general health at least 18 years of age, understands the language of the informed consent, and is willing and able to provide written informed consent and sign/date a health information release (HIPAA form) before any study procedures are performed. 2. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Ocular Inclusion Criteria (Study Eye): 1. Diagnosed with chronic unilateral or bilateral noninfectious posterior segment inflammation (with or without anterior uveitis) that demonstrated a clinical response to ≥1 previous corticosteroid treatment of any localized type (eg, topical steroid 2 to 4 times per day or intra- or peri-ocular injection) or systemic corticosteroid/immunosuppressant treatment with recurrence following treatment indicating chronicity according to the Investigator's judgment. 2. Presence of active posterior segment inflammation as determined by the Investigator. 3. Vitreous haze grade ≥ 2 based on the standardization of uveitis nomenclature (SUN) criteria. 4. Less than 10 anterior chamber cells/high power field determined by slit lamp examination. 5. Not planning to undergo elective ocular surgery during the study. Exclusion Criteria: General Exclusion Criteria: 1. Subjects with known hypersensitivity to any components of YUTIQ. 2. Female subjects who are pregnant or breastfeeding. 3. Has any acute or chronic medical disease or psychiatric condition that, in the opinion of the Investigator, would preclude participation in the study or put the subject at risk due to study treatment or procedures. Ocular Exclusion Criteria (Study Eye): 1. History of anterior uveitis only (without associated uveitis that affected the posterior segment). 2. Presence of a vitreous hemorrhage. 3. Uveitis with infectious etiology. 4. Intraocular inflammation associated with a condition other than non-infectious uveitis (e.g., intraocular lymphoma). 5. Current infectious diseases of the cornea and conjunctiva, mycobacterial infections of the eye, or fungal diseases of ocular structures. 6. Subjects with ACIOL (Anterior Chamber Intraocular Lens) or rupture of the posterior lens capsule. 7. Diagnosis of any form of glaucoma or ocular hypertension at screening, unless the study eye is being treated with ≤2 intraocular pressure (IOP)-lowering medications and/or has been previously treated with an incisional surgical procedure resulting in stable IOP in the normal range (10 to 21 mmHg). 8. Intraocular pressure \>21 mmHg or concurrent therapy at screening with \>2 IOP-lowering pharmacologic agents in the study eye. 9. Any eye surgery within 12 weeks prior to Day 1 of the study. 10. Subjects who are unable to attend scheduled follow-up visits throughout the 12-month study. 11. Has a significant media opacity precluding evaluation of retina and vitreous in the study eye.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05486468 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Uveitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05486468 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 30 participants.
Is NCT05486468 currently recruiting?
Yes, NCT05486468 is actively recruiting participants. Contact the research team at tkeesling@texasretina.com for enrollment information.
Where is the NCT05486468 trial being conducted?
This trial is being conducted at Plano, United States.
Who is sponsoring the NCT05486468 clinical trial?
NCT05486468 is sponsored by Texas Retina Associates. The trial plans to enroll 30 participants.